Literature DB >> 21883724

Total lymphocyte count is a good marker for HIV-related mortality and can be used as a tool for starting HIV treatment in a resource-limited setting.

Helena P W Oudenhoven1, Hinta Meijerink, Rudi Wisaksana, Suryani Oetojo, Agnes Indrati, Andre J A M van der Ven, Henri A G H van Asten, Bachti Alisjahbana, Reinout van Crevel.   

Abstract

OBJECTIVES: Total lymphocyte counts (TLC) may be used as an alternative for CD4 cell counts to monitor HIV infection in resource-limited settings, where CD4 cell counts are too expensive or not available.
METHODS: We used prospectively collected patient data from an urban HIV clinic in Indonesia. Predictors of mortality were identified via Cox regression, and the relation between TLC and CD4 cell counts was calculated by linear regression. Receiver operating characteristics (ROC) curves were used to choose the cut-off values of TLC corresponding with CD4 cell counts <200 and ≤350 cells/μl. Based on these analyses, we designed TLC-based treatment algorithms.
RESULTS: Of 889 antiretroviral treatment (ART)-naïve subjects included, 66% had CD4 cell counts <200 and 81% had 350 ≤ cells/μl at baseline. TLC and CD4 cell count were equally strong predictors of mortality in our population, where ART was started based on CD4 cell count criteria. The correlation coefficient (R) between TLC and √CD4 was 0.70. Optimal cut-off values for TLC to identify patients with CD4 cell counts <200 and ≤350 cells/μl were 1500 and 1700 cells/μl, respectively. Treatment algorithms based on a combination of TLC, gender, oral thrush, anaemia and body mass index performed better in terms of predictive value than WHO staging or TLC alone. In our cohort, such an algorithm would on average have saved $14.05 per patient.
CONCLUSION: Total lymphocyte counts is a good marker for HIV-associated mortality. Simple algorithms including TLC can prioritize patients for HIV treatment in a resource-limited setting, until affordable CD4 cell counts will be universally available.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883724     DOI: 10.1111/j.1365-3156.2011.02870.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  4 in total

1.  A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era.

Authors:  K V Ramana; V Sabitha; Ratna Rao
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  Costs of HIV/AIDS treatment in Indonesia by time of treatment and stage of disease.

Authors:  Adiatma Y M Siregar; Noor Tromp; Dindin Komarudin; Rudi Wisaksana; Reinout van Crevel; Andre van der Ven; Rob Baltussen
Journal:  BMC Health Serv Res       Date:  2015-09-30       Impact factor: 2.655

3.  Clinical spectrum of renal disease in hospitalized HIV/AIDS patients: A teaching hospital experience.

Authors:  Bhupendra Verma; Amrita Singh
Journal:  J Family Med Prim Care       Date:  2019-03

4.  Evaluating total lymphocyte count as a surrogate marker for CD4 cell count in the management of HIV-infected patients in resource-limited settings: a study from China.

Authors:  Jieqing Chen; Wei Li; Xiaojie Huang; Caiping Guo; Ran Zou; Qiuying Yang; Hongwei Zhang; Tong Zhang; Hui Chen; Hao Wu
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.